2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
Barlesi F, Cho B, Goldberg S, Yoh K, Gelatti A, Mann H, Gopinathan A, Bielecka Z, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncology 2024, 20: 2137-2147. PMID: 39023287, PMCID: PMC11508940, DOI: 10.1080/14796694.2024.2354160.Peer-Reviewed Original ResearchNon-small-cell lung cancerStage III non-small-cell lung cancerIII non-small-cell lung cancerPhase III trialsConcurrent chemoradiotherapyUnresectable stage III non-small-cell lung cancerLung cancerPhase III PACIFIC trialGlobal standard of careTargeting PD-L1Early-phase trialsStandard of carePACIFIC trialPD-L1Double-blindIII trialsPlacebo-controlledDurvalumabMonalizumabOleclumabDisease progressionAntitumor activityMonoclonal antibodiesImmunotherapyMAb
2017
Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).
Henick B, Goldberg S, Narayan A, Rossi C, Rodney S, Kole A, Politi K, Gettinger S, Herbst R, Patel A. Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2017, 35: e20652-e20652. DOI: 10.1200/jco.2017.35.15_suppl.e20652.Peer-Reviewed Original ResearchNon-small cell lung cancerTyrosine kinase inhibitorsEGFR-mutant non-small cell lung cancerCtDNA levelsDisease progressionRadiographic progressionTKI therapyEGFR mutationsEGFR mutation-positive non-small cell lung cancerMutation-positive non-small cell lung cancerT790MAnti-PD-1 monotherapyEGFR mutation-positive patientsPD-1 inhibitor monotherapyEGFR-mutant NSCLC patientsSubset of patientsCell lung cancerMutation-positive patientsAssessment of responseLow ctDNA levelsChart reviewClinical characteristicsDurable responsesInhibitor monotherapyNSCLC patients